Reata Announces First Patient Enrolled in Phase 3 CARDINAL Trial of Bardoxolone Methyl in the Treatment of Chronic Kidney Disease Due to Alport Syndrome
IRVING, Texas, Aug. 07, 2017 (GLOBE NEWSWIRE) — Reata Pharmaceuticals, Inc. (NASDAQ:RETA) (“Reata” or the “Company”) today announced the enrollment of the first patient in the Phase 3 portion of the CARDINAL trial of bardoxolone methyl (“bardoxolone”) in patients with chronic kidney disease (“CKD”) caused by Alport syndrome. The purpose of this study is to determine the safety and efficacy of bardoxolone in Alport syndrome patients and to determine if Alport syndrome patients experience improvements in kidney function compared to placebo.
“We are very pleased to begin enrollment of the Phase 3 portion of the CARDINAL study, and we are encouraged by the enthusiasm for bardoxolone that we have experienced within the renal community. We hope to demonstrate that bardoxolone can serve as a meaningful new treatment option for patients with Alport syndrome,” said Warren Huff, Reata’s Chief Executive Officer and President.
About Reata Pharmaceuticals, Inc.
Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates, bardoxolone methyl and omaveloxolone, target the important transcription factor Nrf2 that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling.
This press release includes certain disclosures which contain “forward-looking statements,” including, without limitation, statements regarding the success, cost and timing of our product development activities and clinical trials, our plans to research, develop and commercialize our product candidates, and our ability to obtain and retain regulatory approval of our product candidates. You can identify forward-looking statements because they contain words such as “believes,” “will,” “may,” “aims,” “plans” and “expects.” Forward-looking statements are based on Reata’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to (i) the timing, costs, conduct, and outcome of our clinical trials and future preclinical studies and clinical trials, including the timing of the initiation and availability of data from such trials; (ii) the timing and likelihood of regulatory filings and approvals for our product candidates; (iii) the potential market size and the size of the patient populations for our product candidates, if approved for commercial use, and the market opportunities for our product candidates; and (iv) other factors set forth in Reata’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K, under the caption “Risk Factors.” The forward-looking statements speak only as of the date made and, other than as required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts Corporate: Reata Pharmaceuticals, Inc. (972) 865-2219 email@example.com http://news.reatapharma.com Investor: Vinny Jindal Vice President, Strategy (855) 55-REATA firstname.lastname@example.org Media: Matt Middleman, M.D. LifeSci Public Relations (646) 627-8384 email@example.com
Reata Pharmaceuticals, Inc.